DOI: 10.1055/s-00000054


Issue 01 · Volume 55 · January 2022 · Sample Issue DOI: 10.1055/s-012-52719 Special Issue Psychotropic Drugs and COVID



Mueller, Juliane K.; Riederer, Peter; Müller, Walter E.: Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence?
Veerman, Selene R. T.; Bogers, Jan P. A. M.; Cohen, Dan; Schulte, Peter F. J.: COVID-19: Risks, Complications, and Monitoring in Patients on Clozapine

Original Paper

Bonnet, Udo; Claus, BenediktBernd; Schaefer, Martin; Kuhn, Jens; Nyhuis, Peter; Scherbaum, Norbert; Brüne, Martin; Wakili, Velat; Juckel, Georg: Impact of Psychiatric and Related Somatic Medications on the Duration and Severity of COVID-19: A Retrospective Explorative Multi-center Study from the German Metropolitan Ruhr-area
Plasencia-García, Beatriz Oda; Rico-Rangel, María Isabel; Rodríguez-Menéndez, Gonzalo; Rubio-García, Ana; Torelló-Iserte, Jaime; Crespo-Facorro, Benedicto: Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases

Letter to the Editor

Papadopoulos, Konstantinos I.; Sutheesophon, Warachaya; Aw, Tar-Choon: Anti-SARS-CoV-2 Action of Fluvoxamine may be Mediated by Endothelial Nitric Oxide Synthase